Bimagrumab & Semaglutide for Obesity: Phase 2 Results
New Obesity Treatment Shows Promise with Significant Weight Loss and Lean Mass Preservation Groundbreaking research reveals a novel approach to obesity management, combining the monoclonal antibody bimagrumab with the widely used medication semaglutide. A recent randomized clinical trial demonstrated that this combination therapy resulted in substantial weight reduction – up to 17.8 kg – exceeding … Read more